2.09

0.48% 0.010

After Hours: 2.12 0.03 +1.44%

Allogene Therapeutics Inc (ALLO)

Overview News Price History Option Chain Financials Discussions Forecast

Allogene Therapeutics Inc stock is traded at $2.09, with a volume of 10.84M. It is up +0.48% in the last 24 hours and up +11.17% over the past month. Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).

Previous Close:

$2.08

Open:

$2.08

24h Volume:

10.84M

Relative Volume:

1.00

Market Cap:

$721.37M

Revenue:

$22,000

Net Income/Loss:

$-173.76M

P/E Ratio:

-2.721

EPS:

-0.7681

Net Cash Flow:

$-109.53M

1W Performance:

-5.86%

1M Performance:

+11.17%

6M Performance:

+48.23%

1Y Performance:

+75.63%

1-Day Range:

$2.07

$2.16

1-Week Range:

$2.03

$2.25

52-Week Range:

$0.9842

$4.46

Allogene Therapeutics Inc Stock (ALLO) Company Profile

Name

Allogene Therapeutics Inc

Sector

Healthcare (1100)

Industry

Biotechnology (615)

Phone

(650) 457-2700

Address

210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO

Employee

152

Twitter

@AllogeneTx

Next Earnings Date

2026-08-12

Latest SEC Filings

ALLO's Discussions on Twitter

Compare ALLO vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ALLO Allogene Therapeutics Inc	2.09	717.92M	22,000	-173.76M	-109.53M	-0.7681
VRTX Vertex Pharmaceuticals Inc	529.59	126.07B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	649.81	65.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	916.80	57.70B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	313.04	40.19B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	189.99	39.82B	742.00K	-1.37B	-1.07B	-7.0731

Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-16-26	Upgrade	JP Morgan	Underweight → Neutral
Apr-10-26	Resumed	Jefferies	Buy
Jan-09-26	Upgrade	Citizens JMP	Mkt Perform → Mkt Outperform
Oct-10-25	Downgrade	JP Morgan	Neutral → Underweight
May-14-25	Downgrade	Citizens JMP	Mkt Outperform → Mkt Perform
Mar-14-25	Upgrade	Citizens JMP	Mkt Perform → Mkt Outperform
Aug-08-24	Resumed	Oppenheimer	Outperform
May-31-24	Initiated	Piper Sandler	Overweight
Jan-05-24	Downgrade	Guggenheim	Buy → Neutral
Jan-05-24	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Dec-08-23	Initiated	Citigroup	Buy
Jun-26-23	Resumed	Oppenheimer	Outperform
Mar-21-23	Initiated	Bernstein	Mkt Perform
Jan-24-23	Upgrade	JP Morgan	Neutral → Overweight
Jan-06-23	Upgrade	Robert W. Baird	Neutral → Outperform
Dec-12-22	Downgrade	BofA Securities	Buy → Underperform
Aug-10-22	Downgrade	Raymond James	Outperform → Mkt Perform
Jul-15-22	Upgrade	Goldman	Neutral → Buy
Jun-03-22	Initiated	Robert W. Baird	Neutral
Feb-28-22	Reiterated	B. Riley Securities	Buy
Oct-20-21	Initiated	Cowen	Outperform
Oct-08-21	Downgrade	Goldman	Buy → Neutral
Oct-08-21	Downgrade	Stifel	Buy → Hold
Sep-23-21	Upgrade	Raymond James	Mkt Perform → Outperform
Jun-21-21	Resumed	Jefferies	Buy
May-20-21	Upgrade	Truist	Hold → Buy
May-14-21	Initiated	B. Riley Securities	Buy
Jan-26-21	Upgrade	Stifel	Hold → Buy
Dec-10-20	Resumed	H.C. Wainwright	Buy
Nov-24-20	Initiated	BofA Securities	Buy
Oct-23-20	Initiated	RBC Capital Mkts	Outperform
Jun-01-20	Downgrade	Raymond James	Outperform → Mkt Perform
May-29-20	Reiterated	H.C. Wainwright	Buy
May-19-20	Upgrade	ROTH Capital	Neutral → Buy
May-15-20	Upgrade	Guggenheim	Neutral → Buy
May-14-20	Reiterated	H.C. Wainwright	Buy
May-14-20	Downgrade	SunTrust	Buy → Hold
Apr-13-20	Initiated	SunTrust	Buy
Mar-13-20	Initiated	H.C. Wainwright	Buy
Mar-05-20	Initiated	Stifel	Hold
Feb-24-20	Initiated	Berenberg	Hold
Dec-18-19	Initiated	JMP Securities	Mkt Outperform
Nov-04-19	Initiated	Canaccord Genuity	Buy
Aug-09-19	Initiated	BTIG Research	Buy
Jun-05-19	Initiated	ROTH Capital	Neutral
May-31-19	Initiated	Guggenheim	Neutral
May-23-19	Initiated	Stifel	Hold
Mar-29-19	Initiated	Piper Jaffray	Overweight

View All

Allogene Therapeutics Inc Stock (ALLO) Latest News

Jun 30, 2026

Allogene at H.C. Wainwright conference: cema-cel data lift strategy By Investing.com - Investing.com Canada

Jun 30, 2026

Jun 28, 2026

Enterprise value to EBITDA forward of Allogene Therapeutics, Inc. – NASDAQ:ALLO - TradingView

Jun 28, 2026

Allogene Therapeutics (ALLO) Stock Gets Fair Value Boost After Split Analyst Revisions - Yahoo Finance

Jun 28, 2026

Jun 27, 2026

Price to earnings forward of Allogene Therapeutics, Inc. – NASDAQ:ALLO - TradingView

Jun 27, 2026

Enterprise value to EBITDA forward of Allogene Therapeutics, Inc. – BOATS:ALLO - TradingView

Jun 27, 2026

Enterprise value to revenue forward of Allogene Therapeutics, Inc. – BOATS:ALLO - TradingView

Jun 27, 2026

Price to book forward of Allogene Therapeutics, Inc. – BOATS:ALLO - TradingView

Jun 27, 2026

ALLO Stock Hits 2-Year Highs – Analyst Calls Allogene’s Phase 2 Trial Data To Treat Lymphoma A ‘Home Run’ - Stocktwits

Jun 27, 2026

Enterprise value to EBIT forward of Allogene Therapeutics, Inc. – BOATS:ALLO - TradingView

Jun 27, 2026

Jun 26, 2026

Allogene Therapeutics, Inc. Actuals & Estimates (NASDAQ:ALLO) - TradingView

Jun 26, 2026

Jun 25, 2026

Why is Allogene Therapeutics (ALLO) down 12.2% since last earnings report? - MSN

Jun 25, 2026

ALLO Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026

Allogene Therapeutics unveils strategy to overcome autologous CAR T cell therapy limitations - Traders Union

Jun 25, 2026

Allogene Therapeutics (ALLO) Short Interest & Short Float | Updated Jun 2026 $ALLO - MarketBeat

Jun 25, 2026

Jun 24, 2026

Recent pharma exec shake-ups signal strategic shifts - Pharma Voice

Jun 24, 2026

Jun 23, 2026

Form 4 Allogene Therapeutics Inc For: 23 June By Investing.com - Investing.com Nigeria

Jun 23, 2026

Allogene (ALLO) director Kazam converts 47,700 RSUs and receives 95,400-unit equity grant - Stock Titan

Jun 23, 2026

Allogene Therapeutics (NASDAQ: ALLO) grants director 95,400 RSUs - Stock Titan

Jun 23, 2026

Allogene Therapeutics (ALLO) director receives 144,400 stock options grant - Stock Titan

Jun 23, 2026

Allogene Therapeutics (ALLO) director receives 95,400 RSU equity award - Stock Titan

Jun 23, 2026

Allogene (ALLO) director Owen Witte awarded 95,400 RSUs with deferred delivery - Stock Titan

Jun 23, 2026

[Form 4] Allogene Therapeutics, Inc. Insider Trading Activity - Stock Titan

Jun 23, 2026

Allogene (ALLO) director awarded 95,400 RSUs with deferred share delivery - Stock Titan

Jun 23, 2026

Jun 22, 2026

Form 424B5 Allogene Therapeutics Inc For: 22 June By Investing.com - Investing.com South Africa

Jun 22, 2026

Allogene Therapeutics (NASDAQ: ALLO) doubles authorized shares and files $135M ATM plan - Stock Titan

Jun 22, 2026

Allogene (NASDAQ: ALLO) launches $135M ATM program with TD Cowen at $2.00 ref - Stock Titan

Jun 22, 2026

Jun 19, 2026

Allogene Therapeutics Activates First Clinical Sites for Pivotal Phase 2 Trial of Cema-Cel - CRISPR Medicine News

Jun 19, 2026

Jun 18, 2026

ALLO: All proposals, including director elections and share increase, were approved without contest - TradingView

Jun 18, 2026

ALLO: All proposals passed, including director elections and share authorization increase - TradingView

Jun 18, 2026